SAGE Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
This morning, welcome to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the Smid biotech analysts here at the firm.
It's my pleasure to introduce Sage Therapeutics. Sitting next to me is Jeff Jonas, CEO of the company. And sitting next to him is Mike Cloonan, who is Chief Business Officer. This is going to be a Q&A session. So feel free to raise your hand and ask any questions from the audience. But I will start off the conversation. And maybe just for those very few people who are not as familiar with Sage as the rest of us might be, maybe you could give us a 2-minute introduction about the company, and then we can go from there.
Will do. Thanks. Everyone can hear me, I'm assuming. So thanks, everybody, for coming. The -- so those of you who don't know Sage, we're a company that's focused on central nervous system diseases. We've been public for about 4 years. We recently just announced we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |